ReviewInternational journal of impotence research2025
Post orgasmic illness syndrome: a review.
Review in International journal of impotence research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Post-orgasmic illness syndrome and its effects on self esteem and relationships: a survey.International journal of impotence research · 2026Article
- Artificial intelligence meets medical rarity: evaluating ChatGPT's responses on post-orgasmic illness syndrome.International journal of impotence research · 2025Article
- A Role for IgE in Post-Orgasmic Illness Syndrome: Successful Omalizumab Treatment in Absence of Positive Skin Test to Self Semen.The American journal of case reports · 2025Article
- Postorgasmic illness syndrome benefiting from omalizumab and antidepressant: a case report.Journal of medical case reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
POIS is a rare condition characterized by multisystem symptoms with unclear aetiology. Various attempts have been made to characterize this condition and knowledge is still evolving regarding its aetiology and effective treatment. We have summarized the findings in the English language literature for this rare condition. PubMed search was performed and over 300 English language articles which were screened for relevance. 34 articles were deemed suitable for inclusion. POIS occurs in age range of 21-61 years. Onset of symptoms is usually within 45 min and lasts for an average of 7 days. Primary POIS accounts for approximately half of the cases in literature. The three commonest symptoms were fatigue (68.7), poor concentration (63.9%) and irritation (51.9%). Treatments with variable efficacy which have been proposed include hyposensitisation, antihistamines, alpha blockers, NSAIDS and testosterone replacements. POIS is an important condition which affects the quality of life of men. It is vital that it is managed on a sound scientific basis.
Indexed as
Identifiers
38486122What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.